IMR Press / FBL / Volume 13 / Issue 10 / DOI: 10.2741/2956

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Show Less
1 School of Biomedical Sciences, University of Ulster, Coleraine, UK
2 School of Life and Health Sciences, Aston University, Birmingham, UK
3 School of Biological Sciences, Queens University Belfast, UK

*Author to whom correspondence should be addressed.


Front. Biosci. (Landmark Ed) 2008, 13(10), 3648–3660;
Published: 1 May 2008
(This article belongs to the Special Issue Dipeptidyl peptidase IV and related molecules in health and disease)

Dipeptidyl peptidase IV (DPP IV) is a widely distributed physiological enzyme that can be found solubilized in blood, or membrane-anchored in tissues. DPP IV and related dipeptidase enzymes cleave a wide range of physiological peptides and have been associated with several disease processes including Crohn's disease, chronic liver disease, osteoporosis, multiple sclerosis, eating disorders, rheumatoid arthritis, cancer, and of direct relevance to this review, type 2 diabetes. Here, we place particular emphasis on two peptide substrates of DPP IV with insulin-releasing and antidiabetic actions namely, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The rationale for inhibiting DPP IV activity in type 2 diabetes is that it decreases peptide cleavage and thereby enhances endogenous incretin hormone activity. A multitude of novel DPP IV inhibitor compounds have now been developed and tested. Here we examine the information available on DPP IV and related enzymes, review recent preclinical and clinical data for DPP IV inhibitors, and assess their clinical significance.

Back to top